Our clinical trials of tildacerfont in adults with classic CAH, CAHmelia 203 and CAHmelia 204, are open for screening | LEARN MORE

About Spruce Biosciences

Spruce is committed to transforming the lives of patients living with rare endocrine disorders. Spruce’s wholly-owned product candidate, tildacerfont, is a CRF1 receptor antagonist currently in late-stage clinical trials in adult patients with classic congenital adrenal hyperplasia (CAH).

Learn More

JUNE 2021

In recognition of Congenital Adrenal Hyperplasia (CAH) Awareness Month, Spruce extends its heartfelt support for patients and caregivers. We encourage stakeholders to explore available patient resources to learn more about this rare and chronic condition here. Hear from our CEO on the importance of #CAHAwarenessMonth here.

Challenges of Classic CAH Treatment

Patients and physicians are faced with the difficult choice between the detrimental effects of chronically high adrenal androgen levels or excessive doses of glucocorticoids. This dilemma has persisted for approximately 50 years.

Detrimental effects of chronically high adrenal androgen levels
Harmful consequences of excessive, lifelong glucocorticoid use